Use of serogroup b meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup b meningococcal disease: Recommendations of the advisory committee on immunization practices, 2015

Morbidity and Mortality Weekly Report

Volumn 64, Issue 22, 2015, Pages 608-612

  Folaranmi, Temitope ^a   Rubin, Lorry ^b   Martin, Stacey W ^c   Patel, Manisha ^c   Macneil, Jessica R ^c  

^a Epidemic Intelligence Service CDC

^b Northwell Health   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4CMENB VACCINE; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ADVISORY COMMITTEE; CHILD; CONTRAINDICATIONS; HUMAN; IMMUNIZATION; IMMUNOLOGY; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PRACTICE GUIDELINE; RISK ASSESSMENT; STANDARDS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVISORY COMMITTEES; CHILD; HUMANS; IMMUNIZATION; IMMUNIZATION SCHEDULE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

EID: 84931053811     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Food and Drug Administration. CFR - Code of Federal Regulations Title 21. 2014. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNo de=21:5.0.1.1.4.8.
2. Block SL, Szenborn L, Daly W, et al. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. Vaccine 2015;33:2500–10.
3. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011;18:483–6.
4. Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123–31.
5. Santolaya ME, O’Ryan M, Valenzuela M T, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013;9:2304–10.
6. Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012;379:617–24.
7. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011;7:646–53.
8. Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013;31:1569–75.
9. Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12:597–607.
10. 10. Sheldon EA, Schwartz H, Jiang Q, Giardina PC, Perez JL. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 2012;8:888–95.
11. Vesikari T, Wysocki J, Kieninger D, et al. Immunogenicity, safety, and tolerability, of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine to healthy adolescents. Presented at the 32nd annual meeting of the European Society for Paediatric Infectious Diseases; May 6–10, 2014; Dublin, Ireland.
12. Vesikari T, Diez-Domingo J, Ostergaard L, et al. Safety and immunogenicity of an investigational meningococcal serogroup B bivalent rLP2086 vaccine in healthy adolescents. Presented at the 32nd annual meeting of the European Society for Paediatric Infectious Diseases; May 6–10, 2014; Dublin, Ireland.
13. Bhuyan P, Eiden J, Jones TR, et al., editors. Immunogenicity of human papilloma vaccine coadministered with an investigational bivalent rLP2086 vaccine against meningococcal serogroup B in healthy adolescents. IDWeek; October 8–12, 2014; Philadelphia, PA.
14. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ, ACIP Evidence Based Recommendations Work Group (EBRWG). Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011;29:9171–6.
15. Advisory Committee on Immunization Practices. GRADE tables. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at http://www.cdc.gov/vaccines/acip/recs/GRADE/table-refs.html.
16. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(No. RR-2).
17. Densen P. Complement deficiencies and meningococcal disease. Clin Exp Immunol 1991;86(Suppl 1):57–62.
18. Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun 2004;72:332–7.
19. Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol 2005;43:4811–4.
20. Food and Drug Administration. Bexsero package insert; 2015. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM431447.pdf.
21. Food and Drug Administration. Trumenba package insert; 2014. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf.